Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
153.6 ^USD	+3.38%		+18.58%	-14.85%

23/04	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
23/04	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	25/04
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	25/04
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	24/04
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	24/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	23/04
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	23/04
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	12/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	10/04
Beigene Shrinks Loss by 56% in 2023	29/03
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	22/03
BeiGene, Ltd. Announces Executive Changes	21/03
BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie	16/03
BeiGene recibe la aprobación de la FDA para TEVIMBRA ® para el tratamiento del carcinoma esofágico de células escamosas avanzado o metastásico luego de una quimioterapia previa	15/03
Beigene's Esophageal Cancer Drug Gets US FDA Nod	15/03
BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger Chemotherapie	15/03
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	15/03
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	15/03

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Other languages

Filters